Intellectual Property » NY Settlement May Inform Pharmaceutical Antitrust Cases

NY Settlement May Inform Pharmaceutical Antitrust Cases


The New York Attorney General reached a settlement in an antitrust case between two generic drug manufacturers that had an agreement not to challenge each other’s eligibility for regulatory exclusivity. The theory of harm reflects the U.S. Supreme Court’s recent ruling on reverse payment patent settlements in FTC v. Actavis. The issue in that context was said to arise because a patentee was using its monopoly profits to “prevent the risk of competition.” Under the terms of the New York settlement the parties agreed to pay the state $300,000 and terminate the agreement.

Read full article at:

Get our free daily newsletter

Subscribe for the latest news and business legal developments.

Read this next

AI Vital To Cybersecurity and Cyber Criminals

SEC Complaint Against Company Filed by Ransomware Gang

The new Security and Exchange Commission’s (SEC’s) reporting rules require U.S.-listed companies […]

AI Executive Order Finally Released

The Recruiting Workflow: A Balance Between Technology and Humans

As Legal Operations professionals support their corporate legal departments with digital transformation […]

What to Do When Your Employees Are Using Chatbots

Making Digital Transformation a Core Competency in 2024

Every two or three years, the business world changes, and leaders are […]

Scroll to Top